FMN1 and metabolic dysfunction-associated steatotic liver disease: The potential targets of metformin in the treatment of NAFLD mainly involve cytoplasm, NADP binding, positive regulation of angiogenesis, positive regulation of vasodilation, negative regulation of apoptotic process, steroid binding, angiogenesis, inflammatory response, sequence-specific DNA binding, nitric oxide mediated signal transduction, response to hypoxia, FMN binding, aging, nitric oxide biosynthetic process, exogenous drug catabolic process, protein binding, heme binding, signal transduction, arginine catabolic process, arginine binding.